Results from phase two clinical trials at UT Southwestern Medical Center showed that a suspension of gold nanocrystals taken daily by patients with multiple sclerosis (MS) and Parkinson’s disease (PD) significantly reversed deficits of metabolites linked to energy activity in the brain and resulted in functional improvements.
The findings, published in the Journal of Nanobiotechnology (“Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials”), could eventually help bring this treatment to patients with these and other neurodegenerative diseases, according to the authors.
Gold nanocrystals suspended in a water buffer represent a novel therapeutic agent developed by Clene Nanomedicine for neurodegenerative conditions. This nanomedicine, called CNM-Au8, is being investigated to treat patients with multiple sclerosis and Parkinson’s disease in clinical trials at UT Southwestern. (Illustration: Random 42/Source: Clene Nanomedicine)
Rhodopsin can kill cancer cells keeping the surrounding cells healthy 😤
Considerable time and funding are required in development of new medicines necessary for otherwise untreatable illnesses. Professor Yuki SUDO of Okayama University seeks an innovative form of treatment using rhodopsin, a protein with light-reactive qualities. By extracting it and artificially inserting it into affected cells, it could treat illness simply by exposure to a specific type of light. He has succeeded in using rhodopsin to eliminate cells from cancer, the first such accomplishment ever achieved in the world. In this episode, we introduce the research toward a “light switch” to cure disease.
Nerve cells in the brain demand an enormous amount of energy to survive and maintain their connections for communicating with other nerve cells. In Alzheimer’s disease, the ability to make energy is compromised, and the connections between nerve cells (called synapses) eventually come apart and wither, causing new memories to fade and fail.
A Scripps Research team, reporting in the journal Advanced Science, has now identified the energetic reactions in brain cells that malfunction and lead to neurodegeneration. By using a small molecule to address the malfunction, which occurred in the mitochondria—the cell’s major energy producers—the researchers showed that many neuron-to-neuron connections were successfully restored in nerve cell models derived from human Alzheimer’s patient stem cells. These findings highlight that improving mitochondrial metabolism could be a promising therapeutic target for Alzheimer’s and related disorders.
“We thought that if we could repair metabolic activity in the mitochondria, maybe we could salvage the energy production,” says senior author Stuart Lipton, MD, Ph.D., Step Family Foundation Endowed Professor and Co-Director of the Neurodegeneration New Medicines Center at Scripps Research, and a clinical neurologist in La Jolla, Calif. “In using human neurons derived from people with Alzheimer’s, protecting the energy levels was sufficient to rescue a large number of neuronal connections.”
Roughly 1 in 2 wearers of ventricular assist devices are diagnosed with an infection. The reason for this is the thick cable for the power supply. ETH Zurich researchers have now developed a solution to mitigate this problem.
For many patients waiting for a donor heart, the only way to live a decent life is with the help of a pump attached directly to their heart. This pump requires about as much power as a TV, which it draws from an external battery via a seven-millimeter-thick cable. The system is handy and reliable, but it has one big flaw: Despite medical treatment, the point at which the cable exits the abdomen can be breached by bacteria.
ETH Zurich researcher and engineer Andreas Kourouklis is working to soon make this problem a thing of the past. With the support of ETH Zurich Professor Edoardo Mazza and physicians from the German Heart Center in Berlin, Kourouklis has developed a new cable system for heart pumps that doesn’t cause infections. The findings are published in the journal Biomaterials Advances.
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.
Results from the Phase II umbrella HUDSON study, published in Nature Medicine, demonstrate that the anti PD-L1 antibody, durvalumab, coupled with the ATR inhibitor, ceralasertib, provides the greatest clinical benefit of four combinations evaluated.
This pair had an objective response rate (ORR) of 13.9% compared to just 2.6% with the other tested combinations. Median progression-free survival (PFS) was 5.8 months versus 2.7 months for other combinations, while median overall survival (OS) was 17.4 months versus 9.4 months. In patients with ATM alterations, which should sensitize tumors to ATR inhibitors, the ORR increased to 26.1%. Durvalumab-ceralasertib had a manageable safety profile.